B-type natriuretic peptide is not a volume marker among patients on hemodialysis

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background. Although the cardiac biomarker B-type natriuretic peptide (BNP) is strongly related to mortality in end-stage renal disease (ESRD), whether it is a predictor of weight change or blood pressure (BP) response upon probing dry weight among hypertensive hemodialysis patients remains unknown. The purpose of this study was to examine among people with hypertension on hemodialysis whether BNP is a biomarker of excess volume. Methods. Hypertensive hemodialysis patients (n = 150) were randomized to a control group (n = 50) or an ultrafiltration group (n = 100) and followed up for 30 dialysis treatments. After a baseline run-in of six treatments, those assigned to the ultrafiltration group had dry weight probed over 8 weeks. Forty-fourhour interdialytic ambulatory BP and predialysis BNP were measured at the end of run-in period, at 4 weeks and at 8 weeks. Results. The median BNP concentration was 93 pg/mL (interquartile range 31-257 pg/mL). The magnitude of decline in the BNP depended on the baseline concentration of BNP, but did not require probing dry weight or weight loss. No relationship existed between decline in postdialysis weight upon probing dry weight and baseline BNP. Furthermore, reduction in the BNP was not required for decline in postdialysis weight. Predialysis log BNP modestly predicted ambulatory systolic and pulse pressure independently of other risk factors. No relationship was found between decline in BP upon probing dry weight and baseline BNP. Upon probing dry weight, reduction in BNP was not required for decline in systolic ambulatory BP. Conclusion. Taken together, these data suggest that among hypertensive patients on hemodialysis BNP is not a volume marker.

Original languageEnglish
Pages (from-to)3082-3089
Number of pages8
JournalNephrology Dialysis Transplantation
Volume28
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Brain Natriuretic Peptide
Renal Dialysis
Weights and Measures
Blood Pressure
Ultrafiltration
Biomarkers
Chronic Kidney Failure
Weight Loss
Dialysis

Keywords

  • BNP
  • Dry weight
  • ESRD
  • Hemodialysis
  • Hypertension

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

B-type natriuretic peptide is not a volume marker among patients on hemodialysis. / Agarwal, Rajiv.

In: Nephrology Dialysis Transplantation, Vol. 28, No. 12, 12.2013, p. 3082-3089.

Research output: Contribution to journalArticle

@article{752f5ab55de24595ad90111bbc7e7772,
title = "B-type natriuretic peptide is not a volume marker among patients on hemodialysis",
abstract = "Background. Although the cardiac biomarker B-type natriuretic peptide (BNP) is strongly related to mortality in end-stage renal disease (ESRD), whether it is a predictor of weight change or blood pressure (BP) response upon probing dry weight among hypertensive hemodialysis patients remains unknown. The purpose of this study was to examine among people with hypertension on hemodialysis whether BNP is a biomarker of excess volume. Methods. Hypertensive hemodialysis patients (n = 150) were randomized to a control group (n = 50) or an ultrafiltration group (n = 100) and followed up for 30 dialysis treatments. After a baseline run-in of six treatments, those assigned to the ultrafiltration group had dry weight probed over 8 weeks. Forty-fourhour interdialytic ambulatory BP and predialysis BNP were measured at the end of run-in period, at 4 weeks and at 8 weeks. Results. The median BNP concentration was 93 pg/mL (interquartile range 31-257 pg/mL). The magnitude of decline in the BNP depended on the baseline concentration of BNP, but did not require probing dry weight or weight loss. No relationship existed between decline in postdialysis weight upon probing dry weight and baseline BNP. Furthermore, reduction in the BNP was not required for decline in postdialysis weight. Predialysis log BNP modestly predicted ambulatory systolic and pulse pressure independently of other risk factors. No relationship was found between decline in BP upon probing dry weight and baseline BNP. Upon probing dry weight, reduction in BNP was not required for decline in systolic ambulatory BP. Conclusion. Taken together, these data suggest that among hypertensive patients on hemodialysis BNP is not a volume marker.",
keywords = "BNP, Dry weight, ESRD, Hemodialysis, Hypertension",
author = "Rajiv Agarwal",
year = "2013",
month = "12",
doi = "10.1093/ndt/gft054",
language = "English",
volume = "28",
pages = "3082--3089",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - B-type natriuretic peptide is not a volume marker among patients on hemodialysis

AU - Agarwal, Rajiv

PY - 2013/12

Y1 - 2013/12

N2 - Background. Although the cardiac biomarker B-type natriuretic peptide (BNP) is strongly related to mortality in end-stage renal disease (ESRD), whether it is a predictor of weight change or blood pressure (BP) response upon probing dry weight among hypertensive hemodialysis patients remains unknown. The purpose of this study was to examine among people with hypertension on hemodialysis whether BNP is a biomarker of excess volume. Methods. Hypertensive hemodialysis patients (n = 150) were randomized to a control group (n = 50) or an ultrafiltration group (n = 100) and followed up for 30 dialysis treatments. After a baseline run-in of six treatments, those assigned to the ultrafiltration group had dry weight probed over 8 weeks. Forty-fourhour interdialytic ambulatory BP and predialysis BNP were measured at the end of run-in period, at 4 weeks and at 8 weeks. Results. The median BNP concentration was 93 pg/mL (interquartile range 31-257 pg/mL). The magnitude of decline in the BNP depended on the baseline concentration of BNP, but did not require probing dry weight or weight loss. No relationship existed between decline in postdialysis weight upon probing dry weight and baseline BNP. Furthermore, reduction in the BNP was not required for decline in postdialysis weight. Predialysis log BNP modestly predicted ambulatory systolic and pulse pressure independently of other risk factors. No relationship was found between decline in BP upon probing dry weight and baseline BNP. Upon probing dry weight, reduction in BNP was not required for decline in systolic ambulatory BP. Conclusion. Taken together, these data suggest that among hypertensive patients on hemodialysis BNP is not a volume marker.

AB - Background. Although the cardiac biomarker B-type natriuretic peptide (BNP) is strongly related to mortality in end-stage renal disease (ESRD), whether it is a predictor of weight change or blood pressure (BP) response upon probing dry weight among hypertensive hemodialysis patients remains unknown. The purpose of this study was to examine among people with hypertension on hemodialysis whether BNP is a biomarker of excess volume. Methods. Hypertensive hemodialysis patients (n = 150) were randomized to a control group (n = 50) or an ultrafiltration group (n = 100) and followed up for 30 dialysis treatments. After a baseline run-in of six treatments, those assigned to the ultrafiltration group had dry weight probed over 8 weeks. Forty-fourhour interdialytic ambulatory BP and predialysis BNP were measured at the end of run-in period, at 4 weeks and at 8 weeks. Results. The median BNP concentration was 93 pg/mL (interquartile range 31-257 pg/mL). The magnitude of decline in the BNP depended on the baseline concentration of BNP, but did not require probing dry weight or weight loss. No relationship existed between decline in postdialysis weight upon probing dry weight and baseline BNP. Furthermore, reduction in the BNP was not required for decline in postdialysis weight. Predialysis log BNP modestly predicted ambulatory systolic and pulse pressure independently of other risk factors. No relationship was found between decline in BP upon probing dry weight and baseline BNP. Upon probing dry weight, reduction in BNP was not required for decline in systolic ambulatory BP. Conclusion. Taken together, these data suggest that among hypertensive patients on hemodialysis BNP is not a volume marker.

KW - BNP

KW - Dry weight

KW - ESRD

KW - Hemodialysis

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=84880919258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880919258&partnerID=8YFLogxK

U2 - 10.1093/ndt/gft054

DO - 10.1093/ndt/gft054

M3 - Article

C2 - 23525529

AN - SCOPUS:84880919258

VL - 28

SP - 3082

EP - 3089

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 12

ER -